NVO ▼ -1.2% - Novo Nordisk A/S $NVO Novo Nordisk: Licenses Hengrui’s Oral GLP-1/GIP Drug HRS-1596 in Deal Worth Up to $2.6B ? • Novo will pay $300M upfront for exclusive rights outside mainland China, Hong Kong, Macao and Taiwan. • HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist being developed for weight management and type 2 diabetes, with potential once-weekly oral dosing. • Additional payments are tied to milestones and sales, while closing is expected in Q4 2026 subject to U.S. antitrust clearance and customary conditions. 29-SEP-2026 05:35 AM ET